Articles tagged with Clinical Trials
The BathMat clinical trial evaluates an innovative inflatable pillow designed to make moving intensive care unit patients safer, faster, and less labour-intensive for NHS staff. The trials aim to reduce staff time required for repositioning proned patients and improve patient healthcare outcomes.
Researchers at UC Davis developed a brain-computer interface that translates neural activity into speech in real time. The technology allows individuals with ALS to communicate more naturally and inclusively, with 60% of synthesized words intelligible to listeners.
Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.
The SHARE guidelines offer a systematic checklist to report sham acupuncture control in clinical trials, covering elements of sham acupuncture and related contextual factors. This comprehensive reporting promotes accurate interpretation of trial results and enhances the quality of sham acupuncture-controlled clinical trials.
Long-term data from the Phase 1/2 study of zigakibart demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile in patients with IgA nephropathy. The treatment also led to reductions in serum immunoglobulins, consistent with APRIL pathway inhibition.
The annual Alzheimer's disease drug development pipeline report, led by Dr. Jeffrey Cummings, highlights an increase in active clinical trials and promising drugs, offering reason for optimism. The report assesses 138 drugs currently being studied and notes the growing importance of biomarkers in clinical trials.
The clinical trial demonstrated that the vaccine was safe and fully attenuated, causing no malaria infections in adults. The vaccine has the potential to achieve unprecedented potency and is designed to align with WHO's goals for malaria elimination.
The Phase IIa trial of Rentosertib showed encouraging clinical data, with patients receiving the treatment experiencing significant improvements in lung function compared to placebo. The study also validated the biological mechanism of TNIK inhibition using exploratory biomarkers analyses.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
A recent randomized controlled trial found that a group-based intervention fostering communication and coping skills in a culturally tailored way improved outcomes for Latina breast cancer survivors and their caregivers. The study, published in CANCER journal, demonstrated high engagement among participants and clinically significant i...
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A Kennedy Krieger researcher's work on a promising oral drug, leriglitazone, has shown it can slow the progression of cerebral adrenoleukodystrophy (cALD) in all 11 trial participants. Nearly half of boys treated with the medication appeared to halt disease progression entirely.
A recent study published in JAMA Oncology suggests that modern phase 3 oncology trials often prioritize overall survival over quality of life, which may not accurately reflect patient needs. Future trial designs should focus on improving overall survival and quality-of-life outcomes to better represent patient experiences.
A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
Clinical trials for MASH cirrhosis have shown promising results, particularly with FGF21 analogues like efruxifermin and pegozafermin. The review emphasizes the need for effective interventions targeting advanced disease stages and highlights the importance of surrogate endpoints in accelerating approvals.
Diagnostics.AI has launched the industry's first fully-transparent machine learning platform for clinical real-time PCR diagnostics, delivering algorithmic transparency and per-test auditability. The platform is CE-IVDR certified and backed by over 15 years of experience and millions of successfully processed samples.
A first-of-its-kind clinical trial demonstrates the impact of therapeutic plasma exchange on biological age, reducing it by an average of 2.6 years. The study used multi-omics biomarkers to investigate the effects of TPE on biological age and found promising results for its potential in disease prevention and longevity applications.
A new injection of zilebesiran, an investigational therapeutic, shows sustained reduction in blood pressure for people inadequately controlled with standard treatment. The results could have a big positive impact on those with high-blood pressure affecting around 1 in 3 adults in the UK.
This novel treatment approach yields better weight loss maintenance and cardiovascular risk outcomes compared to standard-of-care treatment. Patient-delivered lifestyle intervention combined with peer support significantly improves weight loss and reduces cardiovascular risk.
The ISSCR has assembled an international consortium to support the adoption of human stem cell-derived disease models for drug discovery and development. This initiative aims to reduce R&D costs and accelerate therapy development, aligning with efforts by regulatory bodies such as the FDA, NIH, and European Commission.
A phase 3 trial announced today demonstrated lorundrostat's safety and effectiveness in reducing blood pressure in patients with resistant hypertension. The treatment, which blocks the production of aldosterone from the adrenal glands, achieved clinically meaningful and sustained reductions in systolic blood pressure.
Researchers at Kyoto University have developed a new non-invasive diagnostic method for insulinomas, which achieved 100% diagnostic accuracy in a Phase II clinical trial. The new method using positron emission tomography (PET) probe successfully detected cases difficult to diagnose through existing methods.
A study found that elevated blood eosinophil counts correlate with Pseudomonas aeruginosa infection in bronchiectasis patients. Inhaled tobramycin reduced symptom burdens and bacterial load without affecting BEC levels, suggesting a targeted therapeutic approach
Surgeons from UCLA Health and Keck Medicine of USC successfully performed the world's first-in-human bladder transplant. The patient, who had lost most of his bladder due to a tumor removal, received a new kidney and bladder through the pioneering technique developed by Drs. Nima Nassiri and Inderbir Gill.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
Researchers at UC San Francisco have identified potential protein markers for frontotemporal dementia (FTD), a form of dementia affecting middle age. The study found changes in RNA regulation and brain connections that could lead to early diagnosis and targeted treatments.
Researchers found that snus cessation led to a clinically significant rise in blood pressure, averaging 3.7 mm Hg, and weight gain of 1.8 kilos in a group of 33 participants. The study suggests that healthcare professionals should monitor blood pressure after snus cessation, especially for individuals with cardiovascular problems.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
A clinical trial found that applying testosterone gel with exercise did not improve physical function in older women recovering from hip fractures. However, the study discovered some positive effects on short-distance mobility, which warrants further investigation. The STEP-HI trial involved 129 women and considered two approaches: tes...
Research found that GLP-1 receptor agonists significantly reduced the risk of heart attacks, strokes, and other cardiovascular events. Treatment with these medications after bariatric surgery was associated with a 67% lower risk of major adverse cardiovascular events or death.
A new analysis of the SELECT trial shows semaglutide reduces major cardiovascular events by 40% within 3-6 months, even before significant weight loss and full target dose. The study found that semaglutide's effects on reducing inflammation, blood sugar, and blood pressure may contribute to its early clinical benefits.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
A new $4 million grant will test whether Prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Computed Tomography (CT) can improve prostate cancer monitoring while reducing screening-related harms. The study aims to reduce the need for biopsies in men with low- or intermediate-risk prostate cancers.
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
A clinical trial finds that moxidectin is more effective than current treatment ivermectin for lymphatic filariasis, a disease affecting millions in Africa. Moxidectin has a persistent effect and may require fewer rounds of treatment, potentially accelerating its elimination.
Insilico Medicine will present detailed Phase IIa data on rentosertib, a novel TNIK inhibitor developed using generative AI, for the treatment of idiopathic pulmonary fibrosis (IPF). The company has previously demonstrated encouraging results from its Phase IIa study, showing favorable safety and tolerability across all dose levels.
A meta-analysis reveals significant racial and ethnic disparities in the reporting of race and ethnicity in clinical trials for pharmacotherapy of mental disorders. The study underscores the importance of equitable recruitment and reporting in clinical trials to ensure inclusive representation of diverse populations.
A Phase III trial shows molecular profiling can safely reduce radiation for women with early-stage endometrial cancer, tailoring treatment to individual tumour characteristics. Nearly half of patients can be spared radiotherapy without compromising cancer control.
A new global clinical trial has demonstrated the benefits of an investigational medication called brensocatib, a DPP-1 inhibitor, in improving bronchiectasis patients' quality of life. The study showed that nearly half of patients remained exacerbation-free one year later and experienced significant improvements in lung function.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
A Phase I clinical trial reveals that HSP-CAR30 CAR-T cell therapy promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients. The treatment exhibits a favorable safety profile, with no dose-limiting toxicities detected.
A world-first clinical trial is being launched in Melbourne, Australia to assess the potential of tumour organoids to predict which chemotherapy drugs will work for newly diagnosed patients with bowel cancer. The trial has the potential to transform current treatment selection practices and improve survival rates and quality of life.
A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
Dr. Jeff Williamson, an internationally recognized geriatrician and clinical trialist, will explore the impact of aging research on improving outcomes for all of us as we age. His work focuses on integrating aging-focused perspectives into clinical trials to ensure that care is aligned with the needs of an aging population.
The framework utilizes consortium blockchain architecture for immutable records, minimizing data falsification and cyberattacks. AI-driven tools ensure objective data collection and analysis, reducing human bias.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
The Society of Thoracic Surgeons has launched a new risk calculator for patients undergoing ascending aorta and aortic root surgery, which provides real-world data collected through the STS Adult Cardiac Surgery Database. The calculator supports more accurate assessments of expected outcomes, including mortality and major morbidity.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A phase II trial found that pembrolizumab significantly reduced recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after surgery. The study suggests that using ctDNA to guide immunotherapy may help prevent relapse in high-risk patients.
A recent clinical trial funded by Swim Across America grant showed that immunotherapy can successfully replace surgery for mismatch repair-deficient (MMRd) solid tumors. This breakthrough treatment enabled 80% of patients to avoid surgery and regain their organs.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
A new CAR NK cell therapy has shown promising results in treating relapsed or refractory blood cancers, particularly AML. The therapy, SENTI-202, employs logic gating to improve specificity and reduce toxicity, and has been associated with complete remissions in seven of nine patients.
A topical BRAF-inhibiting gel, LUT014, improved acneiform rash in 69% of patients with grade 2 or 3 rash and received an EGFR-targeted antibody. The treatment also showed a 33% success rate for the placebo arm, but was associated with similar adverse events.